M Naomi Horiba
3PUBLICATIONS
28CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Jun 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.Sandra J Casak, M Naomi Horiba, Mengdie Yuan
|Oct 07, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.Timil H Patel, Leigh Marcus, M Naomi Horiba
|Aug 12, 2022
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.M Naomi Horiba, Sandra J Casak, Pallavi S Mishra-Kalyani
Pageof 1
Frequent Collaborators
3 joint publications
Richard Pazdur
3 joint publications
Steven J Lemery
3 joint publications
Lola A Fashoyin-Aje
2 joint publications
Sandra J Casak
2 joint publications
Pallavi S Mishra-Kalyani
2 joint publications
Paul G Kluetz
2 joint publications
Yangbing Li
1 joint publications
Pourab Roy
1 joint publications
Julia A Beaver
1 joint publications
Timil H Patel
